$599

Amylyx’s GLP-1 Antagonist Wins in Ph3 Post-Bariatric Surgery Hypoglycemia Study

Amylyx Pharmaceuticals announced positive topline results from the Ph3 LUCIDITY trial (view CT.gov record) evaluating the efficacy and safety of 90mg avexitide (QD SC GLP-1R antagonist) in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery (a common type of bariatric surgery). Below, FENIX provides highlights and insights from the results.

This content is for Read Less members only.
Already a member? Log in here